{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T08:10:29Z","timestamp":1765267829762},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1007\/s00108-006-1755-z","type":"journal-article","created":{"date-parts":[[2006,11,22]],"date-time":"2006-11-22T14:43:23Z","timestamp":1164206603000},"page":"79-88","source":"Crossref","is-referenced-by-count":9,"title":["Pharmakologische R\u00fcckfallpr\u00e4vention bei Alkohol- und Tabakabh\u00e4ngigkeit","Pharmacological relapse prevention in alcohol and tobacco dependence"],"prefix":"10.1007","volume":"48","author":[{"given":"A.","family":"Diehl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1755_CR1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/BF01739647","volume":"239","author":"Feuerlein","year":"1989","unstructured":"Feuerlein W, Kufner H (1989) A prospective multicentre study of in-patient treatment for alcoholics: 18- and 48-month follow-up (Munich Evaluation for Alcoholism Treatment, MEAT). Eur Arch Psychiatry Neurol Sci 239: 144\u2013157","journal-title":"Eur Arch Psychiatry Neurol Sci"},{"key":"1755_CR2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1360-0443.2005.01065.x","volume":"100","author":"Mann","year":"2005","unstructured":"Mann K, Schafer DR, Langle G et al. (2005) The long-term course of alcoholism, 5, 10 and 16 years after treatment. Addiction 100: 797\u2013805","journal-title":"Addiction"},{"key":"1755_CR3","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/j.1530-0277.1998.tb03912.x","volume":"22","author":"Project","year":"1998","unstructured":"Project MATCH Research Group (1998) Matching alcoholism treatments to client heterogeneity: Project MATCH three-year drinking outcomes. Alcohol Clin Exp Res 22: 1300\u20131311","journal-title":"Alcohol Clin Exp Res"},{"key":"1755_CR4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00023210-200418080-00002","volume":"18","author":"Mann","year":"2004","unstructured":"Mann K (2004) Pharmacotherapy of alcohol dependence: a review of the clinical data. CNS Drugs 18: 485\u2013504","journal-title":"CNS Drugs"},{"key":"1755_CR5","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","volume":"295","author":"Anton","year":"2006","unstructured":"Anton RF, O\u2019Malley SS, Ciraulo DA et al. (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295: 2003\u20132017","journal-title":"JAMA"},{"key":"1755_CR6","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1176\/ajp.155.11.1550","volume":"155","author":"Abi-Dargham","year":"1998","unstructured":"Abi-Dargham A, Krystal JH, Anjilvel S et al. (1998) Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [I-123]iomazenil. American Journal of Psychiatry 155: 1550\u20131555","journal-title":"American Journal of Psychiatry"},{"key":"1755_CR7","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1176\/ajp.152.3.332","volume":"152","author":"Tsai","year":"1995","unstructured":"Tsai G, Gastfriend DR, Coyle JT (1995) The glutamatergic basis of human alcoholism. Am J Psychiatry 152: 332\u2013340","journal-title":"Am J Psychiatry"},{"key":"1755_CR8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/BF00171087","volume":"346","author":"Engberg","year":"1992","unstructured":"Engberg G, Hajos M (1992) Alcohol withdrawal reaction as a result of adaptive changes of excitatory amino acid receptors. Naunyn Schmiedebergs Arch Pharmacol 346: 437\u2013441","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1755_CR9","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.7200260","volume":"216","author":"Siegel","year":"1982","unstructured":"Siegel S, Hinson RE, Krank MD et al. (1982) Heroin \u201eoverdose\u201c death: contribution of drug-associated environmental cues. Science 216: 436\u2013437","journal-title":"Science"},{"key":"1755_CR10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/alcalc\/34.2.197","volume":"34","author":"Verheul","year":"1999","unstructured":"Verheul R, van den BW, Geerlings P (1999) A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol 34: 197\u2013222","journal-title":"Alcohol Alcohol"},{"key":"1755_CR11","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jama.1986.03380110055026","volume":"256","author":"Fuller","year":"1986","unstructured":"Fuller RK, Branchey L, Brightwell DR et al. (1986) Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 256: 1449\u20131455","journal-title":"JAMA"},{"key":"1755_CR12","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1530-0277.1991.tb00555.x","volume":"15","author":"Johnsen","year":"1991","unstructured":"Johnsen J, Morland J (1991) Disulfiram implant: a double-blind placebo controlled follow-up on treatment outcome. Alcohol Clin Exp Res 15: 532\u2013536","journal-title":"Alcohol Clin Exp Res"},{"key":"1755_CR13","unstructured":"Ehrenreich H, Jahn H, Heutelbeck K et al. (2002) ALITA \u2013 Neue Wege in der ambulanten Intensivbehandlung von Alkoholabh\u00e4ngigen. In: Mann KF (Hrsg) Neue Therapieans\u00e4tze bei Alkoholproblemen. Pabst, Lengerich, pp 145\u2013160"},{"key":"1755_CR14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0091-3057(90)90174-G","volume":"35","author":"Froehlich","year":"1990","unstructured":"Froehlich JC, Harts J, Lumeng L et al. (1990) Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol Biochem Behav 35: 385\u2013390","journal-title":"Pharmacol Biochem Behav"},{"key":"1755_CR15","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1176\/ajp.156.11.1758","volume":"156","author":"Anton","year":"1999","unstructured":"Anton RF, Moak DH, Waid LR et al. (1999) Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 156: 1758\u20131764","journal-title":"Am J Psychiatry"},{"key":"1755_CR16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/alcalc\/35.2.176","volume":"35","author":"Chick","year":"2000","unstructured":"Chick J, Howlett H, Morgan MY et al. (2000) United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 35: 176\u2013187","journal-title":"Alcohol Alcohol"},{"key":"1755_CR17","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/archpsyc.1997.01830200024004","volume":"54","author":"Cornelius","year":"1997","unstructured":"Cornelius JR, Salloum IM, Ehler JG et al. (1997) Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 54: 700\u2013705","journal-title":"Arch Gen Psychiatry"},{"key":"1755_CR18","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/00004714-200212000-00009","volume":"22","author":"Gastpar","year":"2002","unstructured":"Gastpar M, Bonnet U, Boning J et al. (2002) Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 22: 592\u2013598","journal-title":"J Clin Psychopharmacol"},{"key":"1755_CR19","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jama.284.8.963","volume":"284","author":"Johnson","year":"2000","unstructured":"Johnson BA, Roache JD, Javors MA et al. (2000) Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 284: 963\u2013971","journal-title":"JAMA"},{"key":"1755_CR20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archpsyc.60.1.92","volume":"60","author":"Kiefer","year":"2003","unstructured":"Kiefer F, Jahn H, Tarnaske T et al. (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60: 92\u201399","journal-title":"Arch Gen Psychiatry"},{"key":"1755_CR21","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa011127","volume":"345","author":"Krystal","year":"2001","unstructured":"Krystal JH, Cramer JA, Krol WF et al. (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345: 1734\u20131739","journal-title":"N Engl J Med"},{"key":"1755_CR22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/alcalc\/agg038","volume":"38","author":"Namkoong","year":"2003","unstructured":"Namkoong K, Lee BO, Lee PG et al. (2003) Acamprosate in korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol 38: 135\u2013141","journal-title":"Alcohol Alcohol"},{"key":"1755_CR23","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","volume":"49","author":"O\u2019Malley","year":"1992","unstructured":"O\u2019Malley SS, Jaffe AJ, Chang G et al. (1992) Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 49: 881\u2013887","journal-title":"Arch Gen Psychiatry"},{"key":"1755_CR24","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.281.14.1318","volume":"281","author":"Garbutt","year":"1999","unstructured":"Garbutt JC, West SL, Carey TS et al. (1999) Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 281: 1318\u20131325","journal-title":"JAMA"},{"key":"1755_CR25","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1097\/01.ALC.0000075548.83053.A9","volume":"27","author":"Balldin","year":"2003","unstructured":"Balldin J, Berglund M, Borg S et al. (2003) A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 27: 1142\u20131149","journal-title":"Alcohol Clin Exp Res"},{"key":"1755_CR26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00004714-200106000-00006","volume":"21","author":"Heinala","year":"2001","unstructured":"Heinala P, Alho H, Kiianmaa K et al. (2001) Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol 21: 287\u2013292","journal-title":"J Clin Psychopharmacol"},{"key":"1755_CR27","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","volume":"293","author":"Garbutt","year":"2005","unstructured":"Garbutt JC, Kranzler HR, O\u2019Malley SS et al. (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293: 1617\u20131625","journal-title":"JAMA"},{"key":"1755_CR28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1017\/S1461145704004997","volume":"8","author":"Srisurapanont","year":"2005","unstructured":"Srisurapanont M, Jarusuraisin N (2005) Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 8: 267\u2013280","journal-title":"Int J Neuropsychopharmacol"},{"key":"1755_CR29","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0028-3908(01)00008-9","volume":"40","author":"Rammes","year":"2001","unstructured":"Rammes G, Mahal B, Putzke J et al. (2001) The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 40: 749\u2013760","journal-title":"Neuropharmacology"},{"key":"1755_CR30","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1360-0443.1995.tb01088.x","volume":"90","author":"Littleton","year":"1995","unstructured":"Littleton J (1995) Acamprosate in alcohol dependence: how does it work? Addiction 90: 1179\u20131188","journal-title":"Addiction"},{"key":"1755_CR31","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1530-0277.1998.tb04295.x","volume":"22","author":"Besson","year":"1998","unstructured":"Besson J, Aeby F, Kasas A et al. (1998) Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 22: 573\u2013579","journal-title":"Alcohol Clin Exp Res"},{"key":"1755_CR32","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/alcalc\/36.5.413","volume":"36","author":"Gual","year":"2001","unstructured":"Gual A, Lehert P (2001) Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol 36: 413\u2013418","journal-title":"Alcohol Alcohol"},{"key":"1755_CR33","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/archpsyc.1996.01830080023006","volume":"53","author":"Sass","year":"1996","unstructured":"Sass H, Soyka M, Mann K et al. (1996) Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53: 673\u2013680","journal-title":"Arch Gen Psychiatry"},{"key":"1755_CR34","first-page":"65","volume":"51","author":"Roussaux","year":"1996","unstructured":"Roussaux JP, Hers D, Ferauge M (1996) Does acamprosate diminish the appetite for alcohol in weaned alcoholics?. J Pharm Belg 51: 65\u201368","journal-title":"J Pharm Belg"},{"key":"1755_CR35","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0140-6736(96)91682-7","volume":"347","author":"Whitworth","year":"1996","unstructured":"Whitworth AB, Fischer F, Lesch OM et al. (1996) Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 347: 1438\u20131442","journal-title":"Lancet"},{"key":"1755_CR36","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000019025","volume":"6","author":"Ansoms","year":"2000","unstructured":"Ansoms C, Deckers F, Lehert P et al. (2000) An open study with acamprosate in Belgium and Luxemburg: results on sociodemographics, supportive treatment and outcome. Eur Addict Res 6: 132\u2013140","journal-title":"Eur Addict Res"},{"key":"1755_CR37","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1530-0277.1994.tb00098.x","volume":"18","author":"Mason","year":"1994","unstructured":"Mason BJ, Ritvo EC, Morgan RO et al. (1994) A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 18: 1162\u20131167","journal-title":"Alcohol Clin Exp Res"},{"key":"1755_CR38","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1097\/01.ALC.0000139704.88862.01","volume":"28","author":"Drobes","year":"2004","unstructured":"Drobes DJ, Anton RF, Thomas SE et al. (2004) Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res 28: 1362\u20131370","journal-title":"Alcohol Clin Exp Res"},{"key":"1755_CR39","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.jcp.0000130555.63254.73","volume":"24","author":"Anton","year":"2004","unstructured":"Anton RF, Pettinati H, Zweben A et al. (2004) A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol 24: 421\u2013428","journal-title":"J Clin Psychopharmacol"},{"key":"1755_CR40","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1192\/bjp.165.4.515","volume":"165","author":"Shaw","year":"1994","unstructured":"Shaw GK, Waller S, Majumdar SK et al. (1994) Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry 165: 515\u2013523","journal-title":"Br J Psychiatry"},{"key":"1755_CR41","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1192\/bjp.150.2.164","volume":"150","author":"Shaw","year":"1987","unstructured":"Shaw GK, Majumdar SK, Waller S et al. (1987) Tiapride in the long-term management of alcoholics of anxious or depressive temperament. Br J Psychiatry 150: 164\u2013168","journal-title":"Br J Psychiatry"},{"key":"1755_CR42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/alcalc\/36.4.329","volume":"36","author":"Wiesbeck","year":"2001","unstructured":"Wiesbeck GA, Weijers HG, Lesch OM et al. (2001) Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. Alcohol Alcohol 36: 329\u2013334","journal-title":"Alcohol Alcohol"},{"key":"1755_CR43","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/ajp.152.3.391","volume":"152","author":"Kranzler","year":"1995","unstructured":"Kranzler HR, Burleson JA, Korner P et al. (1995) Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 152: 391\u2013397","journal-title":"Am J Psychiatry"},{"key":"1755_CR44","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1530-0277.1996.tb01686.x","volume":"20","author":"Kabel","year":"1996","unstructured":"Kabel DI, Petty F (1996) A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcohol Clin Exp Res 20: 780\u2013784","journal-title":"Alcohol Clin Exp Res"},{"key":"1755_CR45","first-page":"109","volume":"11","author":"Janiri","year":"1996","unstructured":"Janiri L, Gobbi G, Mannelli P et al. (1996) Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. Int Clin Psychopharmacol 11: 109\u2013117","journal-title":"Int Clin Psychopharmacol"},{"key":"1755_CR46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1530-0277.1992.tb01373.x","volume":"16","author":"Gorelick","year":"1992","unstructured":"Gorelick DA, Paredes A (1992) Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res 16: 261\u2013265","journal-title":"Alcohol Clin Exp Res"},{"key":"1755_CR47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2007-979538","volume":"29","author":"Tiihonen","year":"1996","unstructured":"Tiihonen J, Ryynanen OP, Kauhanen J et al. (1996) Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study. Pharmacopsychiatry 29: 27\u201329","journal-title":"Pharmacopsychiatry"},{"key":"1755_CR48","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1360-0443.1995.tb01013.x","volume":"90","author":"Naranjo","year":"1995","unstructured":"Naranjo CA, Bremner KE, Lanctot KL (1995) Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction 90: 87\u201399","journal-title":"Addiction"},{"key":"1755_CR49","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00004714-200104000-00005","volume":"21","author":"Pettinati","year":"2001","unstructured":"Pettinati HM, Volpicelli JR, Luck G et al. (2001) Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol 21: 143\u2013153","journal-title":"J Clin Psychopharmacol"},{"key":"1755_CR50","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s002130050126","volume":"128","author":"Johnson","year":"1996","unstructured":"Johnson BA, Jasinski DR, Galloway GP et al. (1996) Ritanserin in the treatment of alcohol dependence: a multi-center clinical trial. Ritanserin Study Group. Psychopharmacology 128: 206\u2013215","journal-title":"Psychopharmacology"},{"key":"1755_CR51","first-page":"230","volume":"23","author":"Wiesbeck","year":"1999","unstructured":"Wiesbeck GA, Weijers HG, Chick J et al. (1999) Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Ritanserin in Alcoholism Work Group. Alcohol Clin Exp Res 23: 230\u2013235","journal-title":"Alcohol Clin Exp Res"},{"key":"1755_CR52","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0893-133X(99)00135-9","volume":"22","author":"Kranzler","year":"2000","unstructured":"Kranzler HR, Modesto-Lowe V, Van Kirk J (2000) Naltrexone vs. nefazodone for treatment of alcohol dependence: a placebo-controlled trial. Neuropsychopharmacology 22: 493\u2013503","journal-title":"Neuropsychopharmacology"},{"key":"1755_CR53","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000284626","volume":"22","author":"Bruno","year":"1989","unstructured":"Bruno F (1989) Buspirone in the treatment of alcoholic patients. Psychopathology 22 [Suppl 1]: 49\u201359","journal-title":"Psychopathology"},{"key":"1755_CR54","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1530-0277.1996.tb01644.x","volume":"20","author":"Malec","year":"1996","unstructured":"Malec E, Malec T, Gagne MA et al. (1996) Buspirone in the treatment of alcohol dependence: a placebo-controlled trial. Alcohol Clin Exp Res 20: 307\u2013312","journal-title":"Alcohol Clin Exp Res"},{"key":"1755_CR55","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1530-0277.1994.tb00054.x","volume":"18","author":"Sellers","year":"1994","unstructured":"Sellers EM, Toneatto T, Romach MK et al. (1994) Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 18: 879\u2013885","journal-title":"Alcohol Clin Exp Res"},{"key":"1755_CR56","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1530-0277.1997.tb03733.x","volume":"21","author":"Mueller","year":"1997","unstructured":"Mueller TI, Stout RL, Rudden S et al. (1997) A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res 21: 86\u201392","journal-title":"Alcohol Clin Exp Res"},{"key":"1755_CR57","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archpsyc.61.9.905","volume":"61","author":"Johnson","year":"2004","unstructured":"Johnson BA, Ait-Daoud N, Akhtar FZ et al. (2004) Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry 61: 905\u2013912","journal-title":"Arch Gen Psychiatry"},{"key":"1755_CR58","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.biopsych.2005.02.016","volume":"57","author":"Petrakis","year":"2005","unstructured":"Petrakis IL, Poling J, Levinson C et al. (2005) Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry 57: 1128\u20131137","journal-title":"Biol Psychiatry"},{"key":"1755_CR59","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0014-2999(00)00122-9","volume":"393","author":"Di Chiara","year":"2000","unstructured":"Di Chiara G (2000) Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 393: 295\u2013314","journal-title":"Eur J Pharmacol"},{"key":"1755_CR60","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1111\/j.1460-9568.2005.04105.x","volume":"21","author":"Pakkanen","year":"2005","unstructured":"Pakkanen JS, Jokitalo E, Tuominen RK (2005) Up-regulation of beta2 and alpha7 subunit containing nicotinic acetylcholine receptors in mouse striatum at cellular level. Eur J Neurosci 21: 2681\u20132691","journal-title":"Eur J Neurosci"},{"key":"1755_CR61","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/34413","volume":"391","author":"Picciotto","year":"1998","unstructured":"Picciotto MR, Zoli M, Rimondini R et al. (1998) Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391: 173\u2013177","journal-title":"Nature"},{"key":"1755_CR62","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1176\/appi.ajp.161.7.1211","volume":"161","author":"Brody","year":"2004","unstructured":"Brody AL, Olmstead RE, London ED et al. (2004) Smoking-induced ventral striatum dopamine release. Am J Psychiatry 161: 1211\u20131218","journal-title":"Am J Psychiatry"},{"key":"1755_CR63","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/18019","volume":"398","author":"Garris","year":"1999","unstructured":"Garris PA, Kilpatrick M, Bunin MA et al. (1999) Dissociation of dopamine release in the nucleus accumbens from intracranial self-stimulation. Nature 398: 67\u201369","journal-title":"Nature"},{"key":"1755_CR64","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0014-2999(00)00003-0","volume":"393","author":"Dani","year":"2000","unstructured":"Dani JA, Radcliffe KA, Pidoplichko VI (2000) Variations in desensitization of nicotinic acetylcholine receptors from hippocampus and midbrain dopamine areas. Eur J Pharmacol 393: 31\u201338","journal-title":"Eur J Pharmacol"},{"key":"1755_CR65","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/sj.npp.1300173","volume":"28","author":"Olausson","year":"2003","unstructured":"Olausson P, Jentsch JD, Taylor JR (2003) Repeated nicotine exposure enhances reward-related learning in the rat. Neuropsychopharmacology 28: 1264\u20131271","journal-title":"Neuropsychopharmacology"},{"key":"1755_CR66","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00213-003-1575-y","volume":"171","author":"Olausson","year":"2004","unstructured":"Olausson P, Jentsch JD, Taylor JR (2004) Nicotine enhances responding with conditioned reinforcement. Psychopharmacology 171: 173\u2013178","journal-title":"Psychopharmacology"},{"key":"1755_CR67","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00213-005-0080-x","volume":"184","author":"Smolka","year":"2006","unstructured":"Smolka MN, Buhler M, Klein S et al. (2006) Severity of nicotine dependence modulates cue-induced brain activity in regions involved in motor preparation and imagery. Psychopharmacology 184: 577\u2013588","journal-title":"Psychopharmacology"},{"key":"1755_CR68","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/00001756-200207020-00006","volume":"13","author":"Picciotto","year":"2002","unstructured":"Picciotto MR, Brunzell DH, Caldarone BJ (2002) Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport 13: 1097\u20131106","journal-title":"Neuroreport"},{"key":"1755_CR69","first-page":"865","volume":"22","author":"Pomerleau","year":"1986","unstructured":"Pomerleau OF (1986) Nicotine as a psychoactive drug: anxiety and pain reduction. Psychopharmacol Bull 22: 865\u2013869","journal-title":"Psychopharmacol Bull"},{"key":"1755_CR70","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1469-8986.1989.tb01924.x","volume":"26","author":"Gilbert","year":"1989","unstructured":"Gilbert DG, Robinson JH, Chamberlin CL et al. (1989) Effects of smoking\/nicotine on anxiety, heart rate, and lateralization of EEG during a stressful movie. Psychophysiology 26: 311\u2013320","journal-title":"Psychophysiology"},{"key":"1755_CR71","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s11920-001-0040-z","volume":"3","author":"Laje","year":"2001","unstructured":"Laje RP, Berman JA, Glassman AH (2001) Depression and nicotine: preclinical and clinical evidence for common mechanisms. Curr Psychiatry Rep 3: 470\u2013474","journal-title":"Curr Psychiatry Rep"},{"key":"1755_CR72","first-page":"277","volume":"43","author":"Batra","year":"1997","unstructured":"Batra A, Fagerstrom K (1997) New aspects of tobacco dependency and smoking cessation. Sucht 43: 277\u2013282","journal-title":"Sucht"},{"key":"1755_CR73","unstructured":"Stead LF, Lancaster T (2005) Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev CD001007"},{"key":"1755_CR74","doi-asserted-by":"crossref","unstructured":"Batra A, Buchkremer G (2004) Tabakentw\u00f6hnung. 1. Aufl, Kohlhammer, Stuttgart","DOI":"10.17433\/978-3-17-026572-1"},{"key":"1755_CR75","unstructured":"Fiore MC, Bailey WC, Cohen SJ et al. (2000) Treating tobacco use and dependence. Clinical practice guideline. U.S. Department of Health and Human Services, Public Health Service"},{"key":"1755_CR76","unstructured":"Batra A, Lindinger P, Sch\u00fctz C et al. (2004) AWMF-Leitlinien zur Behandlung der Tabakabh\u00e4ngigkeit. AWMF Leitlinien der DG Sucht"},{"key":"1755_CR77","doi-asserted-by":"crossref","unstructured":"Silagy C, Lancaster T, Stead L et al. (2004) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev CD000146","DOI":"10.1002\/14651858.CD000146.pub2"},{"key":"1755_CR78","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJM199612123352402","volume":"335","author":"Joseph","year":"1996","unstructured":"Joseph AM, Norman SM, Ferry LH et al. (1996) The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 335: 1792\u20131798","journal-title":"N Engl J Med"},{"key":"1755_CR79","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1046\/j.1360-0443.2001.961115472.x","volume":"96","author":"McRobbie","year":"2001","unstructured":"McRobbie H, Hajek P (2001) Nicotine replacement therapy in patients with cardiovascular disease: guidelines for health professionals. Addiction 96: 1547\u20131551","journal-title":"Addiction"},{"key":"1755_CR80","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1001\/jama.1991.03470220090034","volume":"266","author":"Benowitz","year":"1991","unstructured":"Benowitz NL (1991) Nicotine replacement therapy during pregnancy. JAMA 266: 3174\u20133177","journal-title":"JAMA"},{"key":"1755_CR81","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.clpt.2005.08.019","volume":"78","author":"Batra","year":"2005","unstructured":"Batra A, Klingler K, Landfeldt B et al. (2005) Smoking reduction treatment with 4-mg nicotine gum: a double-blind, randomized, placebo-controlled study. Clin Pharmacology Ther 78: 689\u2013696","journal-title":"Clin Pharmacology Ther"},{"key":"1755_CR82","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/14622200500185298","volume":"7","author":"Hughes","year":"2005","unstructured":"Hughes JR, Stead LF, Lancaster T (2005) Nortriptyline for smoking cessation: a review. Nicotine Tob Res 7: 491\u2013499","journal-title":"Nicotine Tob Res"},{"key":"1755_CR83","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199903043400903","volume":"340","author":"Jorenby","year":"1999","unstructured":"Jorenby DE, Leischow SJ, Nides MA et al. (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340: 685\u2013691","journal-title":"N Engl J Med"},{"key":"1755_CR84","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00008877-200209000-00018","volume":"13","author":"Cohen","year":"2002","unstructured":"Cohen C, Perrault G, Voltz C et al. (2002) SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13: 451\u2013463","journal-title":"Behav Pharmacol"},{"key":"1755_CR85","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1021\/jm050069n","volume":"48","author":"Coe","year":"2005","unstructured":"Coe JW, Brooks PR, Vetelino MG et al. (2005) Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48: 3474\u20133477","journal-title":"J Med Chem"},{"key":"1755_CR86","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/3-540-26980-0_12","volume":"166","author":"Cerny","year":"2005","unstructured":"Cerny T (2005) Anti-nicotine vaccination: where are we? Recent Results Cancer Res 166: 167\u2013175","journal-title":"Recent Results Cancer Res"},{"key":"1755_CR87","first-page":"2","volume":"41","author":"Granda","year":"2005","unstructured":"Granda Orive JI (2005) When will the nicotine vaccine be ready? Arch Bronconeumol 41: 2\u20134","journal-title":"Arch Bronconeumol"},{"key":"1755_CR88","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0376-8716(96)01315-4","volume":"44","author":"Kandel","year":"1997","unstructured":"Kandel D, Chen K, Warner LA et al. (1997) Prevalence and demographic correlates of symptoms of last year dependence on alcohol, nicotine, marijuana and cocaine in the U.S. population. Drug Alcohol Depend 44: 11\u201329","journal-title":"Drug Alcohol Depend"},{"key":"1755_CR89","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/j.1530-0277.1994.tb00052.x","volume":"18","author":"Hurt","year":"1994","unstructured":"Hurt RD, Eberman KM, Croghan IT et al. (1994) Nicotine dependence treatment during inpatient treatment for other addictions: a prospective intervention trial. Alcohol Clin Exp Res 18: 867\u2013872","journal-title":"Alcohol Clin Exp Res"},{"key":"1755_CR90","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0899-3289(95)90008-X","volume":"7","author":"Toneatto","year":"1995","unstructured":"Toneatto A, Sobell LC, Sobell MB et al. (1995) Effect of cigarette smoking on alcohol treatment outcome. J Subst Abuse 7: 245\u2013252","journal-title":"J Subst Abuse"},{"key":"1755_CR91","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1046\/j.1360-0443.1998.9368779.x","volume":"93","author":"Bobo","year":"1998","unstructured":"Bobo JK, McIlvain HE, Lando HA et al. (1998) Effect of smoking cessation counseling on recovery from alcoholism: findings from a randomized community intervention trial. Addiction 93: 877\u2013887","journal-title":"Addiction"},{"key":"1755_CR92","first-page":"a","volume":"detoxification","author":"Olbrich","year":"2006","unstructured":"Olbrich R, Troeger S, Nikitopoulos J et al. (2006) Successful smoking reduction during inpatient alcohol detoxification: a controlled clinical trial. European Psychiatry (submitted)","journal-title":"Successful smoking reduction during inpatient alcohol"},{"key":"1755_CR93","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00213-005-0243-9","volume":"184","author":"Mann","year":"2005","unstructured":"Mann K, Ackermann K, Diehl A et al. (2005) Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial. Psychopharmacology 184: 115\u2013121","journal-title":"Psychopharmacology"},{"key":"1755_CR94","first-page":"a","volume":"patients","author":"Diehl","year":"2006","unstructured":"Diehl A, Nakovics H, Croissant B et al. (2006) Galantamine reduces smoking in alcohol dependent patients: a randomized, placebo-controlled trial. Int J Clin Pharmacol Ther (in press)","journal-title":"Galantamine reduces smoking in alcohol dependent"},{"key":"1755_CR95","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/1462220031000073298","volume":"5","author":"Rohsenow","year":"2003","unstructured":"Rohsenow DJ, Monti PM, Colby SM et al. (2003) Naltrexone treatment for alcoholics: effect on cigarette smoking rates. Nicotine Tob Res 5: 231\u2013236","journal-title":"Nicotine Tob Res"},{"key":"1755_CR96","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s002130050872","volume":"142","author":"Hutchison","year":"1999","unstructured":"Hutchison KE, Monti PM, Rohsenow DJ et al. (1999) Effects of naltrexone with nicotine replacement on smoking cue reactivity: preliminary results. Psychopharmacology 142: 139\u2013143","journal-title":"Psychopharmacology"},{"key":"1755_CR97","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1300\/J069v24n02_05","volume":"24","author":"Byars","year":"2005","unstructured":"Byars JA, Frost-Pineda K, Jacobs WS et al. (2005) Naltrexone augments the effects of nicotine replacement therapy in female smokers. J Addict Dis 24: 49\u201360","journal-title":"J Addict Dis"},{"key":"1755_CR98","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1586\/14737175.4.5.751","volume":"4","author":"Johnson","year":"2004","unstructured":"Johnson BA (2004) Uses of topiramate in the treatment of alcohol dependence. Expert Rev Neurother 4: 751\u2013758","journal-title":"Expert Rev Neurother"},{"key":"1755_CR99","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/archinte.165.14.1600","volume":"165","author":"Johnson","year":"2005","unstructured":"Johnson BA, Ait-Daoud N, Akhtar FZ et al. (2005) Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med 165: 1600\u20131605","journal-title":"Arch Intern Med"},{"key":"1755_CR100","first-page":"339","volume":"45","author":"Batra","year":"1999","unstructured":"Batra M, Schupp PE, Buchkremer G (1999) Tabakentw\u00f6hnung bei schwangeren Frauen oder Raucherinnen mit gesundheitlichen Risikofaktoren. Sucht 45: 339\u2013345","journal-title":"Sucht"},{"key":"1755_CR101","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejphar.2005.09.028","volume":"526","author":"Kiefer","year":"2005","unstructured":"Kiefer F, Mann K (2005) New achievements and pharmacotherapeutic approaches in the treatment of alcohol dependence. Eur J Pharmacol 526: 163\u2013171","journal-title":"Eur J Pharmacol"},{"key":"1755_CR102","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3322\/canjclin.55.5.281","volume":"55","author":"Henningfield","year":"2005","unstructured":"Henningfield JE, Fant RV, Buchhalter AR (2005) Pharmacotherapy for nicotine dependence. CA Cancer J Clin 55: 281\u2013299","journal-title":"CA Cancer J Clin"},{"key":"1755_CR103","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1136\/thorax.55.12.987","volume":"55","author":"West","year":"2000","unstructured":"West R, McNeill A, Raw M (2000) Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax 55: 987\u2013999","journal-title":"Thorax"},{"key":"1755_CR104","doi-asserted-by":"crossref","unstructured":"Hughes JR, Stead LF, Lancaster T (2003) Antidepressants for smoking cessation. Cochrane Database Syst Rev CD000031","DOI":"10.1002\/14651858.CD000031"},{"key":"1755_CR105","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2003-42387","volume":"32","author":"Diehl","year":"2003","unstructured":"Diehl A, Smolka MN, Mann K (2003) Pharmakotherapie: R\u00fcckfallprophylaxe bei Alkoholabh\u00e4ngigkeit. Klinikarzt 32: 313\u2013317","journal-title":"Klinikarzt"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-006-1755-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-006-1755-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-006-1755-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T12:01:54Z","timestamp":1707393714000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-006-1755-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":105,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["1755"],"URL":"https:\/\/doi.org\/10.1007\/s00108-006-1755-z","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}